CRVOHealthcare · BiotechnologyThe 6 Wall Street analysts covering CervoMed, Inc. hold a median 12-month price target of $15 — +555.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 19 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CervoMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (84): Smaller than most of the companies we track.
Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRVO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +555.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 12 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 12 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $27 → $18 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 13 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 23 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 19 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Mar 2026 | Roth Capital | Maintains | Buy | — |
| 16 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 4 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CRVO appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Oct 2026, CervoMed, Inc. returned −69.5% against +15.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 4% of US stocks
Cheaper than 59% of US stocks
Cheaper than 65% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CervoMed, Inc. has a market value of $34.9M and an enterprise value of $10.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$30.3M.
Free cash flow in the twelve months to 30 June 2026: −$28.0M.
Trailing P/E: 4.9×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CervoMed, Inc. employs 15 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CervoMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CervoMed reported early results from its Phase 2a study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
Why it matters — The update provides CRVO watchers with information on the company’s clinical evaluation of neflamapimod in this rare aphasia condition.
CervoMed announced pharmacokinetic results for a new 50 mg oral tablet formulation of neflamapimod, which delivers an improved pharmacokinetic profile enabling greater exposure and patient convenience. The company also secured FDA removal of the previous drug exposure limit.
Why it matters — A CRVO watcher would care because an improved tablet formulation and the removal of the FDA exposure limit could enhance neflamapimod's development path and patient usability.
CervoMed Inc. announced that its management will participate in a panel discussion and one-on-one meetings at the 5th Annual ROTH Healthcare Opportunities Conference in New York, NY, on Tuesday, September 29, 2026. The company is a clinical stage firm focused on developing treatments for age-related neurologic disorders.
Why it matters — This participation gives CRVO watchers a chance for company management to connect with healthcare investors and discuss its clinical-stage neurologic disorder programs at a notable industry conference.
CervoMed announced that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral session at the ISFTD 2026 Annual Meeting. The presentation will highlight 12-week biomarker data from the trial.
Why it matters — A late-breaking oral presentation at a major international conference signals notable scientific recognition for CervoMed's neflamapimod program in nfvPPA and offers CRVO watchers an early glimpse at the trial's 12-week biomarker data.
CervoMed Inc. announced that its management will participate in investor conferences during September. The clinical-stage biotechnology company, which develops treatments for age-related brain disorders, released this notice on September 8, 2026.
Why it matters — CRVO watchers would care because the company's management will be presenting to the investor community, offering potential visibility into the company's progress.
The 6 Wall Street analysts covering CervoMed, Inc. have a median 12-month price target of $15, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering CervoMed, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CervoMed, Inc. 33 out of 100 across roughly 4,600 US stocks as at 19 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Oct 2026, CervoMed, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +555.0% from the last close, and Ticker Nerd's factor model ranks CervoMed, Inc. 33 out of 100 as at 19 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CervoMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.
CervoMed, Inc. returned -69.5% over the 12 months to 20 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders.
The most recent item we track (Benzinga, 12 Oct 2026): "CervoMed Shows Progress in Treating Rare Aphasia Condition". CervoMed reported early results from its Phase 2a study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company’s current work centers on advancing CNS-focused therapeutics designed to address degenerative diseases of the brain, with a lead program built around neflamapimod, an investigational orally administered small molecule intended to act on synaptic dysfunction and related neurodegenerative processes. CervoMed’s pipeline targets conditions such as dementia with Lewy bodies and other disorders affecting cognition and neurological function, reflecting its role in the specialized biopharmaceutical sector. As a public company, CervoMed operates within the broader healthcare innovation market, where clinical development, regulatory progress, and therapeutic differentiation are central to its business model. Headquartered in Boston, Massachusetts, CervoMed Inc. serves as a focused small-cap biotechnology participant developing novel approaches for unmet neurological needs.
CEO Dr. John J. Alam M.D. · 15 employees · United States · https://www.cervomed.com
